Mitsubishi Tanabe agreed to acquire NeuroDerm for $39.00/share in cash, total transaction value approximately $1.1B (79% premium over June 9 unaffected price). NeuroDerm's lead asset ND0612 is a late-stage continuous subcutaneous levodopa/carbidopa formulation for Parkinson's disease motor fluctuations, with peak sales potential of ~$1.7B. Largest Japan-Israel pharma deal at the time.